Bo Rode Hansen

Bo Rode Hansen is a seasoned leader in the biotech and pharmaceutical industries, with over two decades of experience driving transformative change. He has held key global and international executive positions and board roles, contributing significantly to company growth through strategic planning in areas such as immunology, oncology and rare diseases. He has substantial experience from building companies from cutting edge life-science technologies and led both private held and public companies through capitalization, strategy setting and transactions. He advises several start-ups and venture funds and has been Entrepreneur in Residence at Novo Holdings/Seeds. Previously, he was CEO of Scandion Oncology, a clinical stage public oncology company and prior to that he was part of the company creation and CEO & President of Genevant Sciences based in Boston MA, a leader in RNA therapeutics and delivery. His career includes positions as global head at Roche pRED, GM of Roche Innovation Center Copenhagen and as executive at Santaris Pharma A/S, where led the company’s integration into Roche following Roche’s aquisition. Bo holds a Ph.D. in Biochemistry from University of Copenhagen, an executive MBA from Henley Business School seconded by executive program from London Business School and Board certificate from Copenhagen Business School.